The global market for pig health and nutrition products is worth about $4.5 billion
a year. Animal Pharm Reports provides you with an extensive review of the major
markets for pig health and nutrition products. It will enable you to access up-to-date
information on the trends, products and key companies in each country and product
sector.
This report will:
let you understand fully the effects of the commercially important pig diseases
enable you to appreciate how the pig health and nutrition industry operates and
analyse those factors driving it forward arm you with the latest intelligence
on over 100 pig health and nutrition products
allow you to examine the structures of 17 major country markets focusing on
pig meat production and pig product sales
provide you with an essential insight into the health and regulatory factors
influencing the local industry in each country market, allowing you to adapt your
national marketing and product development strategies accordingly
tell you how your competitors are performing, enabling you to assess and combat
any future impact they may have on your market share.
The global market for pig health and nutrition products had, in 1999, a total
value of $4.47 billion making the pig sector the second largest after cattle.
Biologicals are becoming more and more important in pigs, especially following
the introduction of newly developed vaccines, into the various markets. Over recent
years, new types of vaccines have changed the structure of the pig biologicals
sector. PRRS and Mycoplasma hyopneumoniae vaccines in particular have led to a
significant increase of the whole sector. As a consequence of the progress in
some parts of the world of disease eradication programmes (such as FMD and Aujeszky's
disease), the usage of according vaccines declined slightly. The outbreaks of
CSF in Europe and public pressure against the local non-vaccination policy accelerated
the process of the development and registration of marker vaccines against that
disease.
Recent years have also seen some remarkable product launches into the segments
for therapeutic anti-infectives and antiparasitics, most of which are derived
from products, which had previously been launched into the cattle segment.
The pace of consolidation, mergers and collaboration agreements in the animal
health industry continues to accelerate, and the past few years have seen some
significant changes in the structure of prominent companies who have a focus on
the pig sector. While it seems to be the policy of some companies to widen their
product portfolio in order to reinforce their presence in the pig segment on a
global level, others have divested certain product lines in order to concentrate
on their strengths in selected segments.
